The Patent Finder

Terms ending in 2030

Immunocore Limited

Every in-force patent on Immunocore Limited's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,361,794Cells Expressing a Modified T Cell Receptor
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 10,420,846Bifunctional Polypeptides
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 10,517,960Bifunctional Polypeptides
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 10,576,162Bifunctional Polypeptides
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 8,519,100Non-naturally occurring T cell receptors
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 9,068,178Nucleic Acid Molecules Encoding Non-Naturally Occurring T Cell Receptors and Cells Thereof
In force
 · High confidence
Immunocore Ltd.In forceHigh confidence
US 10,130,721Bifunctional Polypeptides
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited